SMARCB1 and central nervous system cancer: Zhang and Guo (2019) found that the MEG3/miR-96-5p/MTSS I-BAR domain-containing (MTSS1) axis may be a possible approach for treating gliomas. Recently, it has been reported that MEG3 interacts with miR-377 and PTEN and MEG3 inhibited glioma cells through miR-377/PTEN signals (Wang et al., 2019c). In addition, similar results demonstrated that MEG3 glioma progression by sponging miR-6088 to target the SMARCB1 protein (Gong and Huang, 2020).